Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7179371 | 0.84 | BACE1 (0.39) | BACE1ROCK2DPP4MC4RKCNH2 | |
| SCHEMBL7183390 | 0.74 | ALDH1A1 (0.44) | MAPTDPP4 | |
| SCHEMBL1817856 | 0.70 | BACE1 (0.59) | BACE1ROCK2MAPTPKMMC4R | |
| SCHEMBL2738528 | 0.70 | BACE1 (0.59) | BACE1ROCK2MAPTPKMMC4R | |
| SCHEMBL1817862 | 0.70 | BACE1 (0.59) | BACE1ROCK2MAPTPKMMC4R | |
| SCHEMBL1817859 | 0.70 | BACE1 (0.59) | BACE1ROCK2MAPTPKMMC4R | |
| SCHEMBL7183413 | 0.68 | DPP4 (0.43) | ROCK2DPP4MC4R | |
| SCHEMBL3734306 | 0.68 | BACE1 (0.78) | BACE1ROCK2MAPTPKMDPP4 | |
| SCHEMBL23951521 | 0.67 | BACE1 (0.56) | BACE1ROCK2MAPTPKMMC4R | |
| SCHEMBL22072253 | 0.67 | BACE1 (0.56) | BACE1ROCK2MAPTPKMMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | BACE1 117/4885ROCK2 4217/4885MAPT 3816/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | BACE1 72/4885ROCK2 4102/4885MAPT 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.